|Day's range||5.70 - 5.70|
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Tuesday, June 20, to coincide with the quarterly rebalance. The U.S. equity markets will be closed on Monday, June 19 in observance of the Juneteenth holiday. The changes ensure each index is more representative of its market capitalization range. All companies moving to the S&P MidCap 400 are more representative of the mid-cap m
Doximity (NYSE: DOCS) was viewed as an exciting, fast-growing telehealth company when it went public in 2021. Here's a look at three reasons why Doximity makes for an attractive investment, as well as a potentially important reason to hold off on adding the stock to your portfolio right now. One of the most important numbers for growth-oriented companies is the revenue retention rate, which tells you how much more (or less) customers are spending with a business compared to the previous year.
The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.
After doubling on its first day of trading and nearly doubling again in the next few months, shares of Doximity (NYSE: DOCS) have been on a steady march downward -- losing over 70% of its value from its all-time highs. Doximity's stock was caught in the all-too-common trap of initial public offering (IPO) hype, followed by a year or more of turbulence as the business settled into being a public company. This divergence between share price and operational performance leaves us wondering: Is now the time to buy Doximity at roughly 35% above its all-time lows?
Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SAN FRANCISCO, May 23, 2023--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Dr. Nate Gross, co-founder and chief strategy officer, will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023 at 10:00 a.m. Central Time.
The next time you go looking for the best possible growth stocks to buy, remember that you don't have to reinvent the wheel every time. Every three months, the U.S. Securities and Exchange Commission (SEC) makes just about anyone with over $100 million under management report their trading activities and the latest round of quarterly disclosures. Billionaire Steven Cohen and the fund he manages, Point72, bought nearly 675,000 shares of Doximity (NYSE: DOCS) in the first quarter.
Mixed results from software platform providers show the jury's still out on the business model's viability.
Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, May 16, 2023--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced an integration with MEDITECH, one of the most widely used electronic health record (EHR) systems in the United States. The integration enables medical professionals to launch a Doximity Dialer voice or video telehealth visit directly from MEDITECH’s physician-facing native app, Expanse Now.
SAN FRANCISCO, May 16, 2023--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2023 fourth quarter and fiscal year ended March 31, 2023. The company also announced the appointment of two new senior leadership members, Craig Overpeck as SVP of commercial operations and Ben Greenberg as SVP of commercial products.
Nutex Health Inc. (NUTX) delivered earnings and revenue surprises of 50% and 1.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
It is hard to get excited after looking at Doximity's (NYSE:DOCS) recent performance, when its stock has declined 3.8...
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
In need of healthcare exposure in your portfolio? Consider holding these three promising companies forever.
Agilon (AGL) delivered earnings and revenue surprises of 33.33% and 5.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, April 25, 2023--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter ended March 31, 2023 after market close on May 16, 2023. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.
ELV vs. DOCS: Which Stock Is the Better Value Option?
SAN FRANCISCO, March 23, 2023--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its annual Physician Compensation Report, revealing a slight decline of 2.4% in average pay for doctors in 2022. The report includes self-reported compensation data from over 190,000 U.S. doctors over six years and over 31,000 full-time physicians in the last year alone.
SAN FRANCISCO, March 21, 2023--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it will host an Investor Day on Tuesday, June 6, 2023. The event will be held at the New York Stock Exchange in New York City from 10:30 a.m. to 1:30 p.m. Eastern Time.
Patient investors who would like to see their investments rise 10x have some interesting options right now.
Runaway inflation has been a serious problem for the global economy for nearly two years now. Interest rates that have risen sharply to combat inflation have already begun destabilizing financial systems, and nobody's really sure where we'll go from here.
Today, more than 80% of U.S. doctors already use Doximity. Could this new AI tool secure Doximity's leadership in the market -- and eventually supercharge the stock? Doximity generates revenue from pharmaceutical companies and hospital systems.
A basket balanced evenly across these three businesses could jump-start your journey to becoming a millionaire.
For over a year now, growth stocks have been under a lot of pressure. For example, shares of Doximity (NYSE: DOCS) and SoFi Technologies (NASDAQ: SOFI) are down by more than half from their previous peaks. Shares of Doximity got way ahead of themselves when the all-digital bank made its stock market debut a few years ago.